Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2016
At a glance
- Drugs LOR 2040 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 09 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.